Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Interest & Investment Income: 2020-2025

Historic Interest & Investment Income for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $2.2 million.

  • C4 Therapeutics' Interest & Investment Income fell 37.23% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 23.21%. This contributed to the annual value of $14.4 million for FY2024, which is 47.05% up from last year.
  • Per C4 Therapeutics' latest filing, its Interest & Investment Income stood at $2.2 million for Q3 2025, which was down 9.47% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Interest & Investment Income peaked at $3.9 million during Q1 2024, and registered a low of $69,000 during Q2 2021.
  • Over the past 3 years, C4 Therapeutics' median Interest & Investment Income value was $2.8 million (recorded in 2025), while the average stood at $2.9 million.
  • Per our database at Business Quant, C4 Therapeutics' Interest & Investment Income crashed by 72.20% in 2021 and then skyrocketed by 1,156.62% in 2022.
  • Over the past 5 years, C4 Therapeutics' Interest & Investment Income (Quarterly) stood at $136,000 in 2021, then soared by 1,156.62% to $1.7 million in 2022, then surged by 72.62% to $3.0 million in 2023, then climbed by 10.75% to $3.3 million in 2024, then crashed by 37.23% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.5 million for Q2 2025, and $2.8 million during Q1 2025.